Selecta Biosciences and Sanofi to collaborate on allergy vaccines
Sanofi will use Selecta's proprietary synthetic vaccine particle technology to develop highly targeted immunotherapies against life-threatening allergens.
Selecta Biosciences has announced a new collaboration with Sanofi which will see the two companies team up to discover new immunotherapies for serious allergies.
Under the terms of the global agreement, Sanofi will have an exclusive licence to develop a highly targeted, antigen-specific immunotherapy against a life-threatening food allergen, based on Selecta's proprietary Synthetic Vaccine Particle (SVP) platform.
Sanofi will also have an option to develop two additional candidate immunotherapies for allergies to a specific food or aeroallergen.
Dr Werner Cautreels, president and chief executive officer of Selecta, said he was "very pleased" by Sanofi's interest in the clinical-stage biopharmaceutical company's immunotherapy platform.
"In allergies, as well as autoimmune diseases, organ transplantation and protein replacement therapies, there is a lack of specific, effective and safe treatments to prevent undesired immune reactions," he observed.
"Our approach addresses the underlying causes of these diseases and thereby makes advances beyond today's symptomatic treatments and allergen avoidance strategies."
Selecta's technology enables researchers to engineer nanoparticles that produce immune tolerance for therapeutic and prophylactic applications.
The company will be eligible for pre-clinical, clinical, regulatory and sales milestones amounting to $300 million per allergen indication, as well as double-digit tiered royalties on any product sales resulting from the collaboration.
Related News
-
News Women in Pharma: Moving beyond discussions and into best practice at CPHI Milan
In this second CPHI Milan special of our monthly series, we cover the key takeaways from the Diversity & Wellbeing track held on October 10, 2024. -
News AstraZeneca invests in AI collaboration for cancer drug trials
The British-Swedish pharmaceutical giant is partnering with biotechnology firm Immunai Inc to increase the efficiency of some cancer drug trials. -
News Ozempic and Wegovy prices questioned as Novo Nordisk faces US Senate hearing
The CEO of Novo Nordisk was grilled during a US Senate committee hearing on September 24, 2024, in which the exorbitant prices of the Danish company’s blockbuster drugs Ozempic and Wegovy were called into question. -
News The BIOSECURE Act: implications for the pharma supply chain
On September 9, 2024, the US House of Representatives voted to pass the bill titled the BIOSECURE Act (the Act), which lists several Chinese companies in the pharmaceutical supply chain. The Act will prohibit American companies from contracting or doin... -
News On Track at CPHI Milan: Thermo Fisher Scientific Track Sponsor interview
With CPHI Milan just around the corner, we sat down with some of the sponsors for this year’s conference tracks to discuss the most pressing topics in pharma. -
News CPHI Milan Speaker Spotlight: Pharma Manufacturing and Localisation in Africa
In the run-up to CPHI Milan, we sit down with some of the experts and thought-leaders speaking at this year’s conferences. -
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Eli Lilly licenses rheumatoid arthritis manufacturing in Africa
American pharmaceutical company Eli Lilly has signed a partnership with Egyptian organisation Eva Pharma to localise manufacturing of rheumatoid arthritis treatments in Africa.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance